Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 2/20 | 0.56 |
| ▸ | PDE5A | O76074 | 1/20 | 0.51 |
| ▸ | DCTPP1 | Q9H773 | 2/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21608846 | 0.81 | PIK3R1 (0.51) | PDE1BPDE5ADCTPP1PIK3CDUSP2 | |
| SCHEMBL9980490 | 0.81 | PDE5A (0.47) | PDE1BPDE5ADCTPP1PIK3CDUSP2 | |
| SCHEMBL25241170 | 0.81 | PDE1B (0.57) | PDE1BPDE5AUSP2ALDH1A1CYP1A2 | |
| SCHEMBL24307080 | 0.80 | PDE5A (0.65) | PDE1BPDE5ADCTPP1ALDH1A1MAPK1 | |
| SCHEMBL31042159 | 0.80 | PDE5A (0.65) | PDE1BPDE5ADCTPP1ALDH1A1MAPK1 | |
| SCHEMBL27193449 | 0.79 | PDE1B (0.66) | PDE1BPIK3CDALDH1A1HPGDTSHR | |
| SCHEMBL31533729 | 0.79 | PDE1B (0.66) | PDE1BPIK3CDALDH1A1HPGDTSHR | |
| SCHEMBL24138327 | 0.79 | PDE5A (0.54) | PDE5AALDH1A1HPGDMAPK1SMN1; SMN2 | |
| SCHEMBL31138328 | 0.79 | PDE5A (0.54) | PDE5AALDH1A1HPGDMAPK1SMN1; SMN2 | |
| SCHEMBL7225918 | 0.78 | MEN1 (0.70) | ALDH1A1HPGDTSHRMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365558-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| EP-4219461-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | Medshine Discovery Inc. (CN) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022063094-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | 南京明德新药研发有限公司 | 2022-03-31 | — | — | WO | disclosed |
| CN-113195467-A | Naphthyridine and quinoline derivatives useful as ALK5 inhibitors | 施万生物制药研发IP有限责任公司 | 2021-07-30 | — | — | CN | disclosed |
| US-20210154178-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-10952996-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-23 | — | — | US | disclosed |
| WO-2020123453-A2 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20200188370-A1 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-18 | — | — | US | disclosed |
| US-20130261102-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2013-10-03 | — | — | US | disclosed |
| US-20130261102-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2013-10-03 | — | — | US | disclosed |
| WO-2013078441-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013078441-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013071264-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-05-16 | — | — | WO | disclosed |
| EP-2575462-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Intellikine, LLC (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2011149937-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011149937-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10952996-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | PDE1B 718/4885PDE5A 326/4885DCTPP1 1570/4885 |
| US-20210154178-A1 | ALK5 INHIBITORS | ALK, ACVR1, ACVRL1 | PDE1B 718/4885PDE5A 326/4885DCTPP1 1570/4885 |
| US-11730720-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | PDE1B 718/4885PDE5A 326/4885DCTPP1 1570/4885 |
| US-20230365558-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | CYP3A7, UGT2B7, SFPQ | PDE1B 3302/4885PDE5A 457/4885DCTPP1 3055/4885 |
| US-20130261102-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PDE1B 986/4885PDE5A 1324/4885DCTPP1 1396/4885 |
| US-20200188370-A1 | ALK5 INHIBITORS | ALK, ACVR1, ACVRL1 | PDE1B 718/4885PDE5A 326/4885DCTPP1 1570/4885 |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, AKT2, MTMR1 | PDE1B 576/4885PDE5A 1946/4885DCTPP1 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.